Selected article for: "clinical assessment and disease severity"
Author: Hofmann-Winkler, Heike; Moerer, Onnen; Alt-Epping, Sabine; Bräuer, Anselm; Büttner, Benedikt; Müller, Martin; Fricke, Torben; Grundmann, Julian; Harnisch, Lars-Olav; Heise, Daniel; Kernchen, Andrea; Pressler, Meike; Stephani, Caspar; Tampe, Björn; Kaul, Artur; Gärtner, Sabine; Kramer, Stefanie; Pöhlmann, Stefan; Winkler, Martin Sebastian
Title: Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation
  • Cord-id: iremkqx5
  • Document date: 2020_11_16
    • ID: iremkqx5
    Snippet: Severe acute respiratory syndrome coronavirus 2 cell entry depends on angiotensin-converting enzyme 2 and transmembrane serine protease 2 and is blocked in cell culture by camostat mesylate, a clinically proven protease inhibitor. Whether camostat mesylate is able to lower disease burden in coronavirus disease 2019 sepsis is currently unknown. DESIGN: Retrospective observational case series. SETTING: Patient treated in ICU of University hospital Göttingen, Germany. PATIENTS: Eleven critical ill
    Document: Severe acute respiratory syndrome coronavirus 2 cell entry depends on angiotensin-converting enzyme 2 and transmembrane serine protease 2 and is blocked in cell culture by camostat mesylate, a clinically proven protease inhibitor. Whether camostat mesylate is able to lower disease burden in coronavirus disease 2019 sepsis is currently unknown. DESIGN: Retrospective observational case series. SETTING: Patient treated in ICU of University hospital Göttingen, Germany. PATIENTS: Eleven critical ill coronavirus disease 2019 patients with organ failure were treated in ICU. INTERVENTIONS: Compassionate use of camostat mesylate (six patients, camostat group) or hydroxychloroquine (five patients, hydroxychloroquine group). MEASUREMENTS AND MAIN RESULTS: Clinical courses were assessed by Sepsis-related Organ Failure Assessment score at days 1, 3, and 8. Further, viral load, oxygenation, and inflammatory markers were determined. Sepsis-related Organ Failure Assessment score was comparable between camostat and hydroxychloroquine groups upon ICU admission. During observation, the Sepsis-related Organ Failure Assessment score decreased in the camostat group but remained elevated in the hydroxychloroquine group. The decline in disease severity in camostat mesylate treated patients was paralleled by a decline in inflammatory markers and improvement of oxygenation. CONCLUSIONS: The severity of coronavirus disease 2019 decreased upon camostat mesylate treatment within a period of 8 days and a similar effect was not observed in patients receiving hydroxychloroquine. Camostat mesylate thus warrants further evaluation within randomized clinical trials.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung research: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute ards respiratory distress syndrome and lung spread: 1, 2
    • acute ards respiratory distress syndrome and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7
    • lung injury and lupus erythematosus: 1, 2